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Abstract
 
Active suppression by T regulatory (Tr) cells plays an important role in the downregulation of
T cell responses to foreign and self-antigens. Mouse CD4
 
 
 
 Tr cells that express CD25 possess
remarkable suppressive activity in vitro and in autoimmune disease models in vivo. Thus far,
the existence of a similar subset of CD25
 
 
 
CD4
 
 
 
 Tr cells in humans has not been reported.
Here we show that human CD25
 
 
 
CD4
 
 
 
 Tr cells isolated from peripheral blood failed to pro-
liferate and displayed reduced expression of CD40 ligand (CD40L), in response to T cell recep-
tor–mediated polyclonal activation, but strongly upregulated cytotoxic T lymphocyte–associ-
ated antigen (CTLA)-4. Human CD25
 
 
 
CD4
 
 
 
 Tr cells also did not proliferate in response to
allogeneic antigen-presenting cells, but they produced interleukin (IL)-10, transforming
growth factor (TGF)-
 
 
 
, low levels of interferon (IFN)-
 
 
 
, and no IL-4 or IL-2. Importantly,
CD25
 
 
 
CD4
 
 
 
 Tr cells strongly inhibited the proliferative responses of both naive and memory
CD4
 
 
 
 T cells to alloantigens, but neither IL-10, TGF-
 
 
 
, nor CTLA-4 seemed to be directly
required for their suppressive effects. CD25
 
 
 
CD4
 
 
 
 Tr cells could be expanded in vitro in the
presence of IL-2 and allogeneic feeder cells and maintained their suppressive capacities. These
findings that CD25
 
 
 
CD4
 
 
 
 Tr cells with immunosuppressive effects can be isolated from pe-
 
ripheral blood and expanded in vitro without loss of function represent a major advance to-
wards the therapeutic use of these cells in T cell–mediated diseases.
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Introduction
 
T regulatory (Tr) cells have a key role in the maintenance
of immune tolerance to both self- and harmless foreign an-
tigens. Many subsets of Tr cells have been described and
recently much progress has been made in understanding
their ontogeny, function, and mechanisms of action (for a
review, see reference 1). Some Tr cells do not produce cy-
tokines and suppress T cell responses via a mechanism that
requires direct cell–cell contact (2, 3). Other subsets of Tr
cells produce immunoregulatory cytokines, such as IL-10
and TGF-
 
 
 
, and exert their suppressive functions at least in
part via the effects of these cytokines (4–8).
CD4
 
 
 
 Tr cells that constitutively express the IL-2 recep-
tor (IL-2R) 
 
 
 
 chain (CD25) have been identified in the
mouse (for a review, see references 2 and 3). These
CD25
 
 
 
CD4
 
 
 
 Tr cells show a remarkable suppressive ca-
pacity both in vitro
 
 
 
and in vivo. Transfer of these Tr cells
reduces the pathology of experimentally induced autoim-
mune diseases such as thyroiditis, gastritis, insulin-depen-
dent diabetes mellitus, and colitis (9–12), whereas depletion
of CD25
 
 
 
CD4
 
 
 
 Tr cells results in the development of sys-
temic autoimmune diseases (11, 13, 14).
Murine CD25
 
 
 
CD4
 
 
 
 Tr cells are anergic when stimu-
lated in vitro with anti-CD3 mAbs, but proliferate upon
addition of exogenous IL-2 (15, 16). After TCR-mediated
stimulation, CD25
 
 
 
CD4
 
 
 
 Tr cells suppress the activation
and proliferation of other CD4
 
 
 
 and CD8
 
 
 
 T cells in an
antigen-nonspecific manner (16, 17) via a mechanism that
requires cell–cell contact and, in most systems, is indepen-
dent of production of immunosuppressive cytokines (15,
16). Murine CD25
 
 
 
CD4
 
 
 
 Tr cells constitutively express
cytotoxic T lymphocyte–associated antigen (CTLA)-4 (9),
a negative regulator of T cell activation, and expression of
this molecule may be required for the ability of these cells
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to suppress immune responses in vivo (10, 18). In addition,
CD25
 
 
 
CD4
 
 
 
 Tr cells may act by downregulating the ex-
pression of CD80 and CD86 on APCs (19), although some
reports suggest that APCs are not required for the suppres-
sive activity and indicate that direct T cell–T cell interac-
tion is involved (17).
Considering the potent suppressive capacities of murine
CD25
 
 
 
CD4
 
 
 
 Tr cells, it was critical to determine whether
a similar subset of Tr cells is also present in humans. Re-
sults shown here demonstrate that human CD25
 
 
 
CD4
 
 
 
Tr cells inhibit the proliferative responses of both naive
and memory T cells. In addition, human CD25
 
 
 
CD4
 
 
 
 Tr
cells can be expanded in vitro and maintain not only their
cell surface phenotype but also their potent regulatory
functions.
 
Materials and Methods
 
Purification of CD25
 
 
 
CD4
 
 
 
 Tr Cells.
 
Human peripheral blood
was obtained from healthy donors in accordance with local ethi-
cal committee approval. PBMCs were prepared by centrifugation
over Ficoll-Hypaque gradients (Nycomed Amersham), and
CD4
 
 
 
 T cells were purified by positive or negative selection (by
depletion of CD8, CD11b, CD16, CD19, CD36, and CD56
positive cells) with the CD4
 
 
 
 MultiSort kit or the Untouched
CD4
 
 
 
 T cell isolation kit, respectively (Miltenyi Biotec). After
isolation of CD4
 
 
 
 T cells, CD25
 
 
 
 cells were stained with PE-
coupled anti-CD25 mAbs and purified after the addition of anti-
PE–coupled magnetic beads (Miltenyi Biotec). Alternatively,
CD4
 
 
 
 T cells were purified with magnetic beads directly coupled
to anti-CD25 (Miltenyi Biotec) to facilitate FACS
 
®
 
 analysis. Re-
sults obtained with CD25
 
 
 
CD4
 
 
 
 Tr cells isolated by negative or
positive selection and directly or indirectly coupled CD25 mAbs
were identical. Starting with 2
 
   
 
10
 
8
 
 PBMCs, typically 2–3 
 
 
 
10
 
6
 
 CD25
 
 
 
CD4
 
 
 
 Tr cells were isolated with a purity ranging
from 90–95%. CD25
 
 
 
CD4
 
 
 
 T cells were also collected with a
purity ranging from 70–90%. For purification of CD25
 
 
 
 cells af-
ter in vitro activation of CD25
 
 
 
 cells, CD25
 
 
 
CD4
 
 
 
 T cells were
activated for 48 h with 10
 
  
 
g/ml immobilized anti-CD3 and 1
 
 
 
g/ml soluble anti-CD28 Abs, and CD25
 
 
 
 T cells were purified
as described previously.
 
In Vitro Expansion of T Cell Lines.
 
CD25
 
 
 
CD4
 
 
 
 or CD25
 
 
 
CD4
 
 
 
 T cells were isolated as described previously. T cells (2
 
  
 
10
 
5
 
 cells per milliliter) were stimulated with 1 
 
 
 
g/ml anti-CD3
(OKT3, Orthoclone) in the presence of an allogeneic feeder cell
mixture consisting of 10
 
6
 
 PBMCs per milliliter (irradiated 6,000
rads), 10
 
5
 
 JY cells per milliliter (irradiated 10,000 rads), an EBV-
LCL that expresses high levels of histocompatibility leukocyte an-
tigen (HLA), costimulatory molecules, and cytokines as described
previously (20, 21). All cultures were performed in X-VIVO-15
medium (BioWhittaker) supplemented with 10% FCS (Mascia
Brunelli), 1% pooled human serum, 100 U/ml penicillin/strepto-
mycin (Bristol-Myers Squibb), and 2 mM glutamine (GIBCO
BRL) (hereafter referred to as complete medium). 3 d after acti-
vation, 40 U/ml recombinant interleukin (rIL)-2 (Chiron Corp.)
was added. Cells were split as necessary and fresh medium with
IL-2 was added. T cell lines were restimulated every 14 d. All ex-
periments on expanded cells were performed at least 10 d after
activation.
 
Proliferation and Suppression of T Cells.
 
To analyze prolifera-
tion in response to polyclonal activation, 96-well round-bot-
 
tomed plates (Costar) were coated overnight at 4
 
 
 
C with anti-
CD3 mAbs (10 
 
 
 
g/ml) in 0.1 M Tris, pH 9.5, and washed three
times with PBS. T cells were plated at an initial density of 5
 
  
 
10
 
5
 
 cells per milliliter (100,000 cells per well) in a final volume of
200 
 
 
 
l of complete medium in the absence or presence of 1 
 
 
 
g/
ml soluble anti-CD28 mAbs (BD PharMingen), 10 
 
 
 
g/ml solu-
ble secondary rabbit anti–mouse Abs (Sigma Aldrich),
 
 
 
and/or
100 U/ml IL-2.
To test antigen-specific T cell proliferation, freshly isolated
CD25
 
 
 
CD4
 
 
 
 Tr or CD25
 
 
 
CD4
 
 
 
 T cells (2.5
 
   
 
10
 
5
 
 cells per
milliliter) were stimulated with irradiated (6,000 rads) allogeneic
PBMCs (2.5
 
   
 
10
 
5
 
 cells per milliliter) that had been depleted of
CD3
 
 
 
 cells by negative selection (Dynal). For suppression, in-
creasing numbers (up to 2.5
 
  
 
 10
 
5
 
 cells per milliliter) of freshly
isolated autologous CD25
 
 
 
CD4
 
 
 
 Tr cells were added. Cells
were cocultured in a final volume of 200 
 
 
 
l of complete medium
in 96-well round-bottomed plates. 10 
 
 
 
g/ml control IgG (BD
PharMingen), 10 
 
 
 
g/ml neutralizing anti–IL-10R (3F9; BD
PharMingen), and/or 10 
 
 
 
g/ml or 50 
 
 
 
g/ml anti–TGF-
 
 
 
1,2,3
 
(R&D Systems), or 10 
 
 
 
g/ml F(ab
 
 
 
)
 
2
 
 anti–CTLA-4 (Ancell)
mAbs were added as indicated. For suppression of memory T
cells, cells from expanded CD25
 
 
 
CD4
 
 
 
 T cell lines were cul-
tured with allogeneic APCs (from a donor different from that
used in the allogeneic feeder cell mixture), and increasing num-
bers of expanded autologous CD25
 
 
 
CD4
 
 
 
 Tr cells were added
as described previously. For control experiments, CD25
 
 
 
CD4
 
 
 
T cells purified from in vitro–activated CD25
 
 
 
CD4
 
 
 
 T cells
were added in increasing numbers to freshly isolated autologous
CD25
 
 
 
CD4
 
 
 
 T cells and allogeneic APCs.
After the indicated time, wells were pulsed for 16 h with 1
 
 Ci per well [3H]thymidine (Amersham Pharmacia Biotech).
Cells were harvested and counted in a scintillation counter.
ELISAs. For detection of IL-10, IL-4, IL-2, IFN- , and
TGF- 1, capture ELISAs were performed on supernatants of
cells (106 T cells per milliliter) that had been stimulated with 10
 g/ml immobilized anti-CD3 mAbs with or without 1  g/ml
anti-CD28 and 100 U/ml IL-2, or irradiated CD3-depleted allo-
geneic PBMCs (106 cells per milliliter) for 24 (for IL-2) or 72 h.
ELISAs were performed according to the manufacturer’s instruc-
tions. All capture and detection mAbs were purchased from BD
PharMingen. The limits of detection were as follows: 19 pg/ml
IL-2; 9.4 pg/ml IL-4; 15.6 pg/ml IL-10; 62.5 pg/ml IFN- ; and
62.5 pg/ml TGF- 1.
FACS® Analysis. Anti-CD4, -CD25, -HLA-DR, -CD45RO,
-CD62L, -CD69, and -CD40 ligand (CD40L) mAbs were pur-
chased from Becton Dickinson and were directly coupled to
FITC or PE. Expression of IL-2R  (CD122) and IL-2R 
(CD132) was determined by staining with the relevant biotiny-
lated mAbs (BD PharMingen) and streptavidin-coupled Tricolor
(Caltag). Cells that were resting, or that had been activated with
10  g/ml immobilized anti-CD3, or 10 ng/ml PMA (Sigma
Aldrich) and calcium ionophore (500 ng/ml A23187; Sigma
Aldrich), were incubated with the indicated mAbs for 20 min at
4 C in PBS, 2% FCS, washed once, and analyzed with a FAC-
Scan™ flow cytometer using CELLQuest™ software (Becton
Dickinson). Expression of CTLA-4 was determined by intracyto-
plasmic staining with biotinylated anti–CTLA-4 (BD PharMin-
gen) followed by streptavidin-coupled PE (Caltag). Resting or
activated cells were fixed with 2% formaldehyde, and membranes
were permeabilized by incubation in saponin buffer (PBS, 2%
BSA, and 0.5% saponin; Sigma Aldrich) for 10 min. Staining and
washing were performed in saponin buffer, and cells were washed
once in PBS, 2% BSA before analysis.1297 Levings et al. Brief Definitive Report
Statistical Analysis.  All analysis for statistically significant dif-
ferences were performed with the Student’s paired t test. P values
 0.05 were considered significant. Results are expressed as
means   SEM.
Results and Discussion
Isolation and Cell Surface Phenotype of Human CD25 
CD4  Tr Cells. CD25 CD4  Tr cells are present in
human PBMCs. On average they represent 3.0% (range
1.6–4.4%, n   6) of the total PBMCs and 12.8% (range
9.8–18.1%, n   6) of CD4  T cells. These cells could be
readily isolated with purities  90% (Fig. 1 A). The majority
(82   5.1%) of freshly isolated CD25 CD4  Tr cells also
expressed CD45RO and the percentage of CD25 CD4 
Tr cells expressing HLA-DR was significantly higher than
the CD25 CD4  population (17.3   4.9% vs. 6.4   2.9%,
n   6; Fig. 1 B). In addition, human CD25 CD4  Tr cells
expressed higher levels of the IL-2R  in comparison to
CD25 CD4  T cells (61.9   2.6% vs. 33.1.   2.5%, n  
5; Fig. 1 C) and a subset of freshly isolated CD25 CD4  Tr
cells expressed CTLA-4 (8.4   1.6%, n   6; Fig. 1 E). In
contrast, expression of the IL-2R  and CD62L was equiva-
lent on both populations of T cells. CD25 CD4  Tr cells
and CD25 CD4  T cells were CD3 TCR-     (data not
shown). Thus, human CD25 CD4  Tr cells express mark-
ers that are characteristic of memory T cells and low consti-
tutive levels of CTLA-4, similar to murine CD25 CD4 
Tr cells (9, 10, 15, 17, 18).
After TCR-mediated stimulation, human CD25 CD4 
Tr cells expressed lower levels of activation markers in
comparison to CD25 CD4  T cells. The proportion of
CD40L  cells was 17.3   2.3% in CD25 CD4  Tr cells
versus 28.4   1.8% in the CD25 CD4  T cell subset (P  
0.005), whereas 30.9   7.0% of CD25 CD4  Tr cells ver-
sus 54   9.1% of CD25 CD4  T cells expressed CD69
(P   0.006; Fig. 1 D). Time-course experiments demon-
strated that the reduced levels of CD40L and CD69 on
CD25 CD4  Tr cells were not due to altered kinetics of
expression (data not shown). After activation with PMA
and calcium ionophore there was no statistically significant
difference between expression of CD69 or CD40L on
CD25 CD4  or CD25 CD4  T cells, although in general
fewer CD25 CD4  Tr cells expressed CD40L.
After activation with anti-CD3 mAbs or PMA and cal-
cium ionophore, the percentage of CD25 CD4  Tr cells
expressing CTLA-4 was higher than CD25 CD4  T cells.
In addition, CTLA-4 expression levels were approximately
threefold higher on CD25 CD4  Tr cells (Fig. 1 E). Col-
lectively, these data demonstrate that upon TCR activation
human CD25 CD4  Tr cells have a surface molecule ex-
pression profile that is unique and distinct from other
CD4  T cell subsets.
Proliferation and Cytokine Production by Human CD25 
CD4  Tr Cells. Freshly isolated CD25 CD4  Tr cells
did not proliferate in response to immobilized anti-CD3
mAbs, and the addition of soluble anti-CD28 mAbs re-
sulted in a modest and variable increase in proliferation. In
contrast, cross-linked anti-CD28 mAbs completely re-
versed the unresponsiveness of CD25 CD4  Tr cells to
TCR activation. Addition of exogenous IL-2 partially re-
stored the proliferation of CD25 CD4  Tr cells in re-
sponse to anti-CD3 mAbs, and proliferation was further
enhanced by soluble anti-CD28 mAbs (Fig. 2 A). These re-
Figure 1. Isolation and cell surface phenotype
of human CD25 CD4  Tr cells. CD4  T cells
were isolated from PBMCs and separated into
CD25  and CD25  fractions. Purity (A) and ex-
pression of CD45RO, HLA-DR (B), IL-2R , IL-
2R , and CD62L (C) was determined by FACS®.
CD25 CD4  and CD25 CD4  T cells were cul-
tured either in medium alone or activated with
immobilized anti-CD3 mAbs or PMA and cal-
cium ionophore for 6 (D) or 24 h (E). Cells were
analyzed for surface expression of CD40L and
CD69 (D) and for intracytoplasmic expression of
CTLA-4 (E). Results are representative of six in-
dependent experiments.1298 Human CD25 CD4  T Regulatory Cells
sults indicate that human CD25 CD4  Tr cells have a spe-
cific defect in their ability to proliferate after TCR-medi-
ated activation (15, 16).
Human CD25 CD4  Tr cells were analyzed for their
capacity to produce cytokines. After stimulation with im-
mobilized anti-CD3 mAbs, with or without soluble anti-
CD28 mAbs, no detectable levels of IL-2, IL-10, IL-4,
TGF- , or IFN-  could be measured (data not shown). In
contrast, when stimulated with anti-CD3 and soluble
anti-CD28 mAbs in the presence of exogenous IL-2,
CD25 CD4  Tr cells produced significant levels of IL-4,
IL-10, IFN- , and TGF-  (Table I). Under these stimula-
tion conditions, CD25 CD4  Tr cells had a cytokine pro-
file that was comparable to CD25 CD4  T cells. In con-
trast, differences in cytokine production were observed
after activation with allogeneic APCs. Both CD25 CD4 
and CD25 CD4  T cells produced IL-10, TGF- , and
IFN- , but no IL-4. However, the striking difference be-
tween the CD25 CD4  and CD25 CD4  T cell popula-
tions was that the CD25  cells failed to secrete IL-2, indi-
cating that these cells have a specific defect in production
of IL-2. Interestingly, CD25 CD4  Tr cells consistently
produced less IFN-  upon alloantigen stimulation than did
CD25 CD4  T cells.
Human CD25 CD4  Tr Cells Suppress the Proliferative
Responses of Naive CD25 CD4  T Cells to Alloantigens.
We investigated the regulatory properties of CD25 CD4 
Tr cells by testing their ability to suppress the proliferative
responses of naive CD25 CD4  T cells to alloantigens.
CD25 CD4  T cells were stimulated with allogeneic
APCs and increasing numbers of autologous CD25 CD4 
Tr cells were added. Addition of as few as 2,500
CD25 CD4  Tr cells to 50,000 CD25 CD4  T cells re-
sulted in a reduced proliferation of CD25 CD4  T cells.
At a ratio of 1:1, CD25 CD4  Tr cells inhibited the pro-
liferation of naive CD25 CD4  T cells by an average of
75.0   2.9% (n   9; Fig. 2 B). The CD25 CD4  Tr cells
themselves failed to proliferate in response to alloantigens.
Furthermore, CD25 CD4  Tr cells suppressed the prolif-
eration of CD25 CD4  T cells in response to PHA in the
presence of APCs (by an average of 81.2   5.0%, n   6;
data not shown) and to immobilized anti-CD3 alone (by an
average of 79.4   14.6%, n   3; data not shown). These
latter data indicate that CD25 CD4  Tr cells have a direct
suppressive effect on T cells that is independent of APCs,
similar to murine CD25 CD4  Tr cells (17). In addition,
CD25 CD4  Tr cells suppressed production of IFN-  and
IL-2 by CD25 CD4  T cells activated with anti-CD3
mAbs or allogeneic APCs (data not shown).
To demonstrate that this suppressive capacity was an in-
trinsic property of T cells constitutively expressing CD25
in vivo, we tested whether CD25 CD4  T cells which ex-
pressed CD25 after activation in vitro showed regulatory
effects. To this aim, CD25 CD4  T cells were activated
with anti-CD3 and anti-CD28 mAbs, and after 48 h the
CD25  T cells were isolated and tested for their ability to
suppress freshly isolated autologous CD25  T cells. As
shown in Fig. 2 C, T cells that became CD25  after in
vitro activation proliferated in response to alloantigens and
Figure 2. CD25 CD4  Tr cells are anergic and suppress proliferation
to alloantigens. Purified CD25 CD4  Tr cells (100,000 cells per well)
were tested for their ability to proliferate in response to immobilized anti-
CD3 mAbs ( CD3; 10  g/ml) in the absence or presence of soluble anti-
CD28 mAbs ( CD28; 1  g/ml), secondary rabbit anti–mouse Abs
( CD28 CL; 10  g/ml), and/or 100 U/ml IL-2. After 72 h of culture,
[3H]thymidine was added for an additional 16 h (A). CD25 CD4  T cells
(50,000 cells per well) were tested for their ability to proliferate in re-
sponse to allogeneic APCs in the absence or presence of increasing num-
bers of autologous CD25 CD4  Tr cells (B). CD25 CD4  T cells were
activated to induce CD25 expression. After 48 h, T cells that became
CD25  (CD25 i) were purified and tested for their ability to suppress
proliferation of CD25   T cells in response to alloantigens (C).
CD25 CD4  T cells were activated by alloantigens with or without
CD25 CD4  Tr cells (1:1 ratio) in the presence of the indicated mAbs
(10  g/ml). Numbers represent the percent reduction in proliferation
compared with culture in the absence of CD25 CD4  Tr cells (D). For
B–D, after 96 h, [3H]thymidine was added for an additional 16 h. Results
are representative of six independent experiments for A, nine for B, and
three for C and D.
Table I. Cytokine Production by CD25 CD4  Tr Cells
Stimuli Cells IL-2 IL-4 IL-10 IFN-  TGF- 
 CD3/28   IL-2 CD25  ND 153 1148 5723 1322
 CD3/28   IL-2 CD25  ND 94 840 9773 1225
allogeneic APCs CD25   19  9 298 527 509
allogeneic APCs CD25  99.5  9 251 5744 637
Purified cells were stimulated as indicated and supernatants were
collected after 24 (for IL-2) or 72 h. The amount of cytokine was
determined by ELISA. Data represent the average values (pg/ml) of
pooled data from four independent experiments. Cytokine production
by allogeneic APCs alone has been subtracted.1299 Levings et al. Brief Definitive Report
enhanced, rather than suppressed, the response of CD25 
CD4  T cells. These data indicate that inhibition of T cell
proliferation is a unique property of cells which constitu-
tively express CD25 in vivo.
Several studies show that some subsets of Tr cells, such as
type 1 Tr (Tr1) and Th3 cells, secrete IL-10 and/or TGF- 
and suppress immune responses via production of these cy-
tokines (4–8). Since CD25 CD4  Tr cells produced both
IL-10 and TGF-  upon stimulation with allogeneic APCs
(Table I), the role of these cytokines on inhibition of allo-
geneic responses by human CD25 CD4  Tr cells was in-
vestigated. As shown in Fig. 2 D, addition of neutralizing
anti–IL-10R or anti–TGF-  mAbs had no significant effect
on the ability of CD25 CD4  Tr cells to suppress the pro-
liferation of CD25 CD4  T cells in response to alloanti-
gens. In three independent experiments, an average of
67.2   6.0% suppression was observed in the presence
of 10  g/ml of control IgG, 63.8   5.8% with 10  g/ml
of anti–IL-10R, and 69.0   3.4% with 10  g/ml of anti–
TGF-  mAbs. Similar results were obtained with a fivefold
higher concentration of anti–TGF-  mAbs (data not
shown). Addition of both anti–IL-10R and anti–TGF- 
mAbs resulted in a slight, but not statistically significant, re-
versal of suppression mediated by CD25 CD4  Tr cells
(from 67.2   6.0% to 52.4   5.7%, P   0.06).
F(ab )2 fragments from Abs which specifically block the
ability of CTLA-4 to bind to CD80/86, without affecting
signals via CD28, have been shown previously to inhibit
the production of TGF-  by Tr1 cells (22). Addition of the
same blocking anti–CTLA-4 mAbs had no significant effect
on the suppressive activity of CD25 CD4  Tr cells. These
data suggest that despite the fact that CD25 CD4  Tr cells
express high levels of CTLA-4 (Fig. 1 E), this molecule is
not required for their suppressive activity.
Human CD25 CD4  Tr Cells Can Be Expanded In Vi-
tro. We have shown previously that human Tr1 cells
which have been cloned and expanded in vitro maintain
their regulatory activity (6). Using a protocol similar to
that described for Tr1 cells, we determined whether
CD25 CD4  Tr cells could be expanded. CD25 CD4 
Tr cells did not proliferate in response to anti-CD3 alone
(Fig. 2 A), but when activated with anti-CD3 mAbs in
the presence of an allogeneic feeder cell mixture and ex-
ogenous IL-2, an expansion which was similar to
CD25 CD4  T cells was obtained (20–30-fold increase at
day 14). In vitro–expanded human CD25 CD4  Tr cells
remained positive for CD25 even after culture for  1 mo
(Fig. 3 A). In contrast, all CD25 CD4  T cells expressed
CD25 after activation, but the expression gradually de-
creased with time. Persistent expression of CD25 has also
been observed in murine CD25 CD4  Tr cells activated
in vivo (23).
Similar to freshly isolated CD25 CD4  Tr cells, the
proportion of in vitro–expanded CD25 CD4  Tr cells ex-
pressing CD40L after activation with anti-CD3 mAbs was
consistently lower in comparison to CD25 CD4  T cells
(12.7   3.3% vs. 36.9   8.3%, P   0.01). However, in
contrast to freshly isolated cells, cultured CD25 CD4  Tr
cells expressed normal levels of CD69 after polyclonal
TCR-mediated activation (Fig. 3 B). Thus, reduced up-
regulation of CD40L is also a characteristic of expanded
CD25 CD4  Tr cells. As expected, cultured CD25 
CD4  and CD25 CD4  T cells expressed similar levels of
both CD40L and CD69 after activation with PMA and cal-
cium ionophore. In vitro–expansion of CD25 CD4  Tr
cells did not alter their constitutive expression of CTLA-4,
and they continued to express this inhibitory molecule at
significantly higher levels than their CD25 CD4  counter-
parts (Fig. 3 C).
In Vitro–expanded CD25 CD4  Tr Cells Remain Anergic
and Retain Their Suppressive Capacity. In vitro–expanded
CD25 CD4  Tr cells failed to proliferate in response to
anti-CD3 mAbs alone, and proliferation could only be
completely restored by the addition of exogenous IL-2
(Fig. 4 A). Moreover, cultured CD25 CD4  Tr cells failed
Figure 3. Expansion and cell surface phenotype of CD25 CD4  Tr
cells. CD25  and CD25 CD4  T cells were purified and activated with
anti-CD3 mAbs, allogeneic feeder cell mixture, and exogenous IL-2.
Cells were split as necessary and after 2 wk were analyzed by FACS® for
expression of CD25 and CD4 (A). In parallel, cells were analyzed for cell
surface expression of CD40L and CD69 after activation for 6 h with im-
mobilized anti-CD3 mAbs or PMA and calcium ionophore (B). Consti-
tutive levels of CTLA-4 expression was determined by intracytoplasmic
staining (C). Results are representative of three independent experiments.1300 Human CD25 CD4  T Regulatory Cells
to proliferate in response to alloantigens and retained their
ability to suppress the proliferation of autologous CD25 
CD4  T cells (at a 1:1 ratio, an average of 64   3.8%, n  
3, suppression was observed; Fig. 4 B). These data indicate
that CD25 CD4  Tr cells expanded in vitro maintain their
regulatory functions and behave similarly to freshly isolated
CD25 CD4  Tr cells. Since in these experiments the
CD25 CD4  responder T cells had been activated previ-
ously and expanded in vitro, these data demonstrate that
CD25 CD4  Tr cells suppress not only the response of
freshly isolated naive CD25 CD4  T cells, but also of pre-
viously activated memory CD25 CD4  T cells (Fig. 4
B). Finally, similar to observations with freshly isolated
CD25 CD4  Tr cells, the suppression mediated by in
vitro–expanded CD25 CD4  Tr cells was not reversed by
the addition of neutralizing anti–IL-10R, anti–TGF- , or
anti–CTLA-4 mAbs (Fig. 4 C).
In this study we show that human CD4  T cells that ex-
press CD25 in vivo are a unique subset of Tr cells. Human
CD25 CD4  Tr cells are anergic, fail to produce IL-2, con-
stitutively express CTLA-4, and suppress the proliferation of
naive CD4  T cells as described for murine CD25 CD4  Tr
cells (2, 3). In addition, after polyclonal TCR-mediated acti-
vation, human CD25 CD4  Tr cells strongly upregulate
CTLA-4, display reduced expression of CD40L, and pro-
duce cytokines. CD25 and CTLA-4 remain constitutively
expressed on in vitro–expanded human CD25 CD4  Tr
cells, while after activation, upregulation of CD40L is still de-
fective. More interestingly, in vitro–expanded CD25 CD4 
Tr cells retain their potent suppressive activity, even towards
previously activated memory T cells. The observation that
functional Tr cells can be expanded in vitro and can regulate
responses of memory T cells is of great clinical relevance for
the use of CD25 CD4  Tr cells as a cellular therapy in T
cell–mediated diseases where there are preactivated T cells.
The role of immunoregulatory cytokines in the suppres-
sion mediated by CD25 CD4  Tr cells remains an open
question. Alloantigen-activated CD25 CD4  Tr cells did
not proliferate but produced IL-10, IFN- , and TGF- ,
and indeed possessed a profile of cytokine production
which is comparable to Tr1 cells (i.e., IL-10 IFN-  TGF-
  IL-4 IL-2 /low) (6). However, we observed only a slight
reversal of suppression in the presence of both neutralizing
anti–IL-10R and anti–TGF-  mAbs, which is consistent
with previous observations that production of IL-10 and
TGF-  is dispensable for the regulatory function of
CD25 CD4  Tr cells (15, 16). On the other hand, in a
murine model of experimentally induced colitis, both IL-
10 and TGF-  were found to be required for suppression
mediated by CD25 CD4  Tr cells (5, 10). The basis for
this discrepancy in the involvement of IL-10 and TGF-  is
unclear. CD25 CD4  Tr cells have the capacity to pro-
duce IL-10 and TGF- , but production of these cytokines
may depend on their maturation state and the environmen-
tal context in which they are activated.
Previous reports demonstrated that direct cell–cell con-
tact is required for murine CD25 CD4  Tr cells to exert
their suppressive effects (15, 16). Despite constitutive and
persistent expression of CTLA-4, anti–CTLA-4 mAbs
failed to abrogate the suppressive activity of human
CD25 CD4  Tr cells. These data are in agreement with a
study indicating that signals via CTLA-4 were dispensable
for suppression by mouse CD25 CD4  Tr cells in vitro
(15). However, more recent reports show that expression
of CTLA-4 is essential for suppression mediated by these
cells (10, 18). It is possible that suppression of proliferation
operates via mechanisms which differ depending on the
stimuli and microenvironment, or that human and mouse
CD25 CD4  Tr cells act through different mechanisms.
Finally, suppression is not simply due to consumption of
Figure 4. Cultured CD25 CD4  Tr cells retain their suppressive capacity. CD25  and CD25 CD4  T cells were purified and activated with anti-
CD3 mAbs, allogeneic feeder cell mixture, and exogenous IL-2. After 14 d of culture, T cells were tested for their ability to proliferate in response to 10
 g/ml anti-CD3 mAbs in the absence or presence of 1  g/ml soluble anti-CD28 mAbs and/or 100 U/ml IL-2 (A). Cultured CD25 CD4  T cells
(50,000 cells per well) were tested for their ability to proliferate in response to alloantigens in the absence or presence of increasing numbers of in vitro–
cultured, autologous CD25 CD4  Tr cells (B). Cultured CD25 CD4  T cells were activated by allogeneic APCs (from a donor different from that used
for expansion) with or without CD25 CD4  Tr cells (1:1 ratio) in the presence of the indicated mAbs (10  g/ml). Numbers represent the percent re-
duction in proliferation compared with culture in the absence of CD25 CD4  Tr cells (C). For all cultures, after 48 h, [3H]thymidine was added for an
additional 16 h. Results are representative of three independent experiments.1301 Levings et al. Brief Definitive Report
IL-2 as murine CD25 CD4  Tr cells suppressed IL-2 pro-
duction at the transcriptional level (15). In addition, human
CD4  T cells which expressed CD25 after activation in
vitro did not suppress responses of CD25 CD4  T cells,
indicating that high expression of CD25 does not simply
result in sequestration of IL-2.
Human CD25 CD4  Tr cells expand in vitro and main-
tain their unique cell surface marker profile and suppressive
functions. To our knowledge, these data represent the first
report of in vitro–expansion of human CD25 CD4  T
suppressor cell lines. The ability to isolate and expand hu-
man CD25 CD4  Tr cells will allow the further biological
and biochemical characterization of this unique T cell sub-
set and expedite progress towards clinical use of Tr cells as a
cellular therapy for T cell–mediated diseases.
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